当高血压遇到心率增快，β受体阻滞剂如何选择？( 五 )

内容策划：马腾
内容审核：冯依璠
题图来源：站酷海洛、文献内容、住友
参考文献：
[1]. INOUE T, ISEKI K, ISEKI C, et al. Higher heart rate predicts the risk of developing hypertension in a normotensive screened cohort[J]. Circ J, 2007, 71(11):1755-1760.
[2]. PALATINI P, DORIGATTI F, ZAETTA V, et al. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study[J]. J Hypertens, 2006, 24(9):1873-1880.
[3]. BENETOS A, ADAMOPOULOS C, BUREAU J M, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period[J]. Circulation, 2002, 105(10):1202-1207.
[4]. B?HM M, REIL J C, DANCHIN N, et al. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH[J]. J Hypertens, 2008, 26(1):18-25.
[5]. ZHANG M, HAN C, WANG C, et al. Association of resting heart rate and cardiovascular disease mortality in hypertensive and normotensive rural Chinese[J]. J Cardiol, 2017, 69(5):779-784.
[6]. ZHAO M X, ZHAO Q, ZHENG M, et al. Effect of resting heart rate on the risk of all-cause death in Chinese patients with hypertension: analysis of the Kailuan follow-up study[J]. BMJ Open, 2020, 10(3):e032699.
[7]. PALATINI P, THIJS L, STAESSEN J A, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension[J]. Arch Intern Med, 2002, 162(20):2313-2321.
[8]. SAXENA A, MINTON D, LEE D C, et al. Protective role of resting heart rate on all-cause and cardiovascular disease mortality[J]. Mayo Clin Proc, 2013, 88(12):1420-1426.
[9]. JULIUS S, PALATINI P, KJELDSEN S E, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension[J]. Am J Cardiol, 2012, 109(5):685-692.
[10]. LONN E M, RAMBIHAR S, GAO P, et al. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGE/ TRANSCEND[J]. Clin Res Cardiol, 2014, 103(2):149-159.
[11]. 高血压心率管理多学科共识组．中国高血压患者心率管理多学科专家共识（2021年版）[J]．中国医学前沿杂志（电子版）,2021,13（4）：38-48．
[12]. 赵连友,孙宁玲,孙英贤,李玉明,李南方,田刚,谢良地,郭艺芳,李悦,冯颖青,苏海,李勇.α/β受体阻滞剂在高血压治疗中应用的中国专家共识[J].中华高血压杂志,2016,24(06):521-526.
[13]. 第八届中华肾脏病学会慢性肾脏病高血压治疗专家协作组.α/β受体阻滞剂在慢性肾脏病高血压治疗中的实践指南[J].中华医学杂志， 2013,93(48):3812-3816.
[14]. 郭冀珍. 阿罗洛尔——无代谢不良反应的肾上腺素β受体阻滞药[J]. 中国新药与临床杂志， 2008,27(4):313-316.